824 related articles for article (PubMed ID: 32880909)
21. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
[TBL] [Abstract][Full Text] [Related]
22. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
Blauvelt A; Armstrong AW; Langley RG; Gebauer K; Thaçi D; Bagel J; Guenther LC; Paul C; Randazzo B; Flavin S; Hsu MC; You Y; Reich K
J Dermatolog Treat; 2022 Jun; 33(4):2317-2324. PubMed ID: 34348574
[TBL] [Abstract][Full Text] [Related]
25. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
[TBL] [Abstract][Full Text] [Related]
26. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
27. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Leonardi C; Reich K; Foley P; Torii H; Gerdes S; Guenther L; Gooderham M; Ferris LK; Griffiths CEM; ElMaraghy H; Crane H; Patel H; Burge R; Gallo G; Shrom D; Leung A; Lin CY; Papp K
Dermatol Ther (Heidelb); 2020 Jun; 10(3):431-447. PubMed ID: 32200512
[TBL] [Abstract][Full Text] [Related]
30. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
Teeple A; Muser E
J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
[No Abstract] [Full Text] [Related]
31. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
[TBL] [Abstract][Full Text] [Related]
33. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.
Hebert AA; Bobonich MA; Rodriguez Capriles C; Gallo G; Li L; Somani N; Ridenour T; Wang Y; Edson-Heredia E; Becker EM
Pediatr Dermatol; 2022 Jan; 39(1):55-60. PubMed ID: 34931346
[TBL] [Abstract][Full Text] [Related]
34. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
Diels J; Thilakarathne P; Cameron C; McElligott S; Schubert A; Puig L
Br J Dermatol; 2020 Aug; 183(2):276-284. PubMed ID: 31652347
[TBL] [Abstract][Full Text] [Related]
35. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
[No Abstract] [Full Text] [Related]
36. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
38. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
[TBL] [Abstract][Full Text] [Related]
39. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K
BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264
[TBL] [Abstract][Full Text] [Related]
40. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
Teeple A; Fitzgerald T
J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
